Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BTK

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: BTK. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-002915-14 Sponsor Protocol Number: MOR208C205 Start Date*: 2015-12-30
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II, Two Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined with Idelalisib or Venetoclax in Patients with Relapsed or Refractory CLL/...
    Medical condition: Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    21.1 100000004864 10003910 B-cell small lymphocytic lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004553-72 Sponsor Protocol Number: J2N-OX-JZNM(LOXO-BTK-20019) Start Date*: 2021-07-14
    Sponsor Name:Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) HU (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000108-41 Sponsor Protocol Number: 062-HEM-102 Start Date*: 2019-02-06
    Sponsor Name:Sunesis Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies
    Medical condition: Male or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    20.1 100000004851 10047802 Waldenstrom's macroglobulinaemias HLT
    20.1 100000004864 10008948 Chronic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004341-17 Sponsor Protocol Number: PCYC-1123-CA Start Date*: 2014-10-16
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-003631-36 Sponsor Protocol Number: RG_12-124 Start Date*: 2015-02-10
    Sponsor Name:University of Birmingham
    Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002887-17 Sponsor Protocol Number: IM006-016 Start Date*: 2016-03-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects with Moderate...
    Medical condition: Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate With or Without TNF Inhibitors
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000540-25 Sponsor Protocol Number: FIL_KLIMT Start Date*: 2019-06-25
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study
    Medical condition: BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003128-30 Sponsor Protocol Number: Uni-Koeln-1776 Start Date*: 2016-05-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
    Medical condition: relapsed lymphocyte-predominant Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000064-42 Sponsor Protocol Number: MS200527-0081 Start Date*: 2016-07-27
    Sponsor Name:Merck KGaA
    Full Title: Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003213-18 Sponsor Protocol Number: RHMCAN1129 Start Date*: 2017-01-13
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000043-49 Sponsor Protocol Number: LOXO-BTK-20022 Start Date*: 2021-08-16
    Sponsor Name:Loxo Oncology Inc
    Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NO (Completed) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000259-28 Sponsor Protocol Number: 54179060LYM3003 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma.
    Medical condition: Mature B-Cell Neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000694-23 Sponsor Protocol Number: PCYC-1112-CA Start Date*: 2012-08-08
    Sponsor Name:Pharmacyclics LLC an Abbvie Company
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia...
    Medical condition: relapsed or refractory CLL/SLL
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10060671 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003564-37 Sponsor Protocol Number: PRN1008-005 Start Date*: 2016-04-21
    Sponsor Name:Principia Biopharma Australia Pty Ltd
    Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn...
    Medical condition: Pemphigus: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006611-29 Sponsor Protocol Number: 80009 Start Date*: 2022-06-28
    Sponsor Name:University Medical Centre Utrecht Department of Vascular Surgery
    Full Title: A randomized placebo-controlled double-blind trial studying the effect of antiplatelet monotherapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel + aspirin) on the occurrence of athero...
    Medical condition: (Chronic) Peripheral (occlusive) arterial disease (PAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000970-12 Sponsor Protocol Number: INCB50465-204 Start Date*: 2017-10-13
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor.
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) BE (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001448-21 Sponsor Protocol Number: MS200527-0086 Start Date*: 2017-02-16
    Sponsor Name:Merck KGaA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Effic...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) CZ (Completed) PL (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003286-26 Sponsor Protocol Number: PCYC-1140-IM Start Date*: 2017-04-18
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Dis...
    Medical condition: Chronic Graft Versus Host Disease (cGVHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) AT (Completed) HR (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:52:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA